Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Research in Real-Life Ltd
With
Orion Corporation, Orion Pharma
A recent observational study by Price et al carried out using the UK's General Practice Research Database (CPRD) to compare asthma-related outcomes for different inhaled corticosteroid (ICS) inhaler devices, using Easyhaler and dry powder inhalers (DPIs).
Age
6–80
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
(1) Aged: 6-80 years - stratified 6-11 years; 12-60 years; ≥61 years to allow paediatrics and adolescent / adult sub analyses; and to allow for the exclusion of elderly (aged 61+) smokers and ex-smokers if required.
(2) On-going asthma therapy: ≥2 prescriptions for asthma during the outcome period (i.e. ≥1 prescription (for any asthma therapy) in addition to the prescription for ICS at IPD (initiation / step-up/ switch).
(3) Evidence of active asthma:
1. Initiation - a diagnostic code for asthma
2. Step-up / Switch - ≥2 prescriptions for asthma (at least one of which is for ICS) at different points in time during the baseline year PLUS a diagnostic code for asthma.
(4) Have at least one year of up-to-standard (UTS) baseline data and at least one year of UTS outcome data (following the IPD).
You may not be if
Patients will be excluded from the analysis if they have:
(1) Had a COPD read code at any time; and/or
(2) Had any chronic respiratory disease, except asthma, at any time; and/or
(3) Patients on maintenance oral steroids during baseline year; and/or
(4) Multiple ICS prescriptions at IPD.
Clareo Health | Real Life Effectiveness of Easyhaler (Orion)
